A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age

Vaccine

Volumn 24, Issue 18, 2006, Pages 3964-3970

  Kitchin, Nicholas ^a   Southern, Joanna ^b   Morris, Rhonwen ^b   Hemme, Fabienne ^a   Cartwright, Keith ^b   Watson, Michael ^c   Miller, Elizabeth ^b  

^a Sanofi Pasteur MSD Ltd   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c SANOFI PASTEUR   (France)

Author keywords

Acellular pertussis; Combination vaccine; Safety

Indexed keywords

ACELLULAR VACCINE; ACT HIB DTP; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; NEISVAC C; ORAL POLIOMYELITIS VACCINE; PEDIACEL; PENTACEL; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANOREXIA; ARTICLE; ASTHMA; BRONCHIOLITIS; CHICKENPOX; CLINICAL TRIAL; CONJUGATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CRYING; DIARRHEA; DIPHTHERIA; DISEASE EXACERBATION; DRUG ERUPTION; DRUG FEVER; ECZEMA; FEBRILE CONVULSION; FEMALE; GASTROENTERITIS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INFANT; INFANTILE HYPOTONIA; INFECTION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MALE; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MULTICENTER STUDY; NORMAL HUMAN; OTITIS MEDIA; PERTUSSIS; PHYSICAL ACTIVITY; PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TETANUS; UNITED KINGDOM; VACCINATION REACTION; VIRAL BRONCHIOLITIS; VIRUS INFECTION; VOMITING; WHEEZING;

BACTERIAL VACCINES; BODY TEMPERATURE; CRYING; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEEDING BEHAVIOR; FEMALE; GREAT BRITAIN; HUMANS; INFANT; IRRITABLE MOOD; MALE; MENINGOCOCCAL VACCINES; MOTOR ACTIVITY; POLIOVIRUS VACCINE, ORAL; VACCINES, ACELLULAR; VACCINES, COMBINED;

EID: 33646493654     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.018     Document Type: Article

References (17)

1. Edwards K.M., Decker M.D., and Mortimer E.A. Pertussis vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (1999), WB Saunders, Philadelphia 293-344
2. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions after DTP vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR CDC Surveill Summ 45 (1996) 22-35
3. http://www-nt.who.int/vaccines/globalsummary/Immunization/CountryProfile Select.cfm [accessed 08.02.05]
4. Miller E., Ashworth L.A.E., Redhead K., Thornton C., Waight P.A., and Coleman T. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15 1 (1997) 51-60
5. In: Salisbury D.M., and Begg N.T. (Eds). Immunisation against infectious disease (1996), TSO, London 45
6. Halperin S.A., McDonald J., Samson L., et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin Invest Med 25 6 (2002) 243-251
7. Tejedor J.C., Omenaca F., Garcia-Sicilia J., Verdaguer J., Van Esso D., Esporrin C., et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 23 12 (2004) 1109-1115
8. Miller E. Overview of recent clinical trials of acellular pertussis vaccine. Biologicals 27 (1999) 79-86
9. http://www.hpa.org.uk/infections/topics_az/vaccination/cover.htm [accessed 08.02.05]
10. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 (1996) 349-355
11. Olin P., Rasmusson F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 (1997) 1569-1577
12. Personal communication, sanofi pasteur.
13. Le Saux N., Barrowman N.J., Moore D.L., Whiting S., Scheifele D., and Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112 5 (2003) e348-e353
14. Scheifele D.W., Halperin S.A., Morris R., Dery P., Lebel M., et al. Immunization monitoring program, active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 14 3 (2003) 213-219
15. Offit P.A., Quarles J., Gerber M.A., Hackett C.J., Marcuse E.K., et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system?. Pediatrics 109 1 (2002) 124-129
16. Miller E., Andrews N., Waight P., and Taylor B. Bacterial infections, immune overload and MMR vaccination. Arch Dis Child 88 (2003) 222-223
17. Bedford H., and Elliman D. Misconceptions about the new combination vaccine. BMJ 329 (2004) 411-412